Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;145(2):383-392.
doi: 10.1007/s00432-018-2799-x. Epub 2018 Nov 22.

Non-invasive profiling of protease-specific elastin turnover in lung cancer: biomarker potential

Jeppe Thorlacius-Ussing  1   2 , Stephanie Nina Kehlet  1 , Sarah Rank Rønnow  1 , Morten Asser Karsdal  1 , Nicholas Willumsen  3
Affiliations

Non-invasive profiling of protease-specific elastin turnover in lung cancer: biomarker potential

Jeppe Thorlacius-Ussing et al. J Cancer Res Clin Oncol. 2019 Feb.

Abstract

Purpose: Elastin is a signature protein of lungs. Increased elastin turnover driven by altered proteolytic activity is an important part of lung tumorigenesis. Elastin-derived fragments have been shown to be pro-tumorigenic, however, little is known regarding the biomarker potential of such elastin fragments. Here, we present an elastin turnover profile by non-invasively quantifying five specific elastin degradation fragments generated by different proteases.

Methods: Elastin fragments were assessed in serum from patients with stage I-IV non-small cell lung cancer (NSCLC) (n = 40) and healthy controls (n = 30) using competitive ELISAs targeting different protease-generated fragments of elastin: ELM12 (generated by matrix metalloproteinase MMP-9 and -12), ELM7 (MMP-7), EL-NE (neutrophil elastase), EL-CG (cathepsin G) and ELP-3 (proteinase 3).

Results: ELM12, ELM7, EL-NE and EL-CG were all significantly elevated in NSCLC patients (n = 40) when compared to healthy controls (n = 30) (ELM12, p = 0.0191; ELM7, p < 0.0001; EL-NE, p < 0.0001; EL-CG, p < 0.0001). ELP-3 showed no significant difference between patients and controls (p = 0.8735). All fragments correlated positively (Spearman, r: 0.69-0.81) when compared pairwise, except ELM12 (Spearman, r: 0.042-0.097). In general, all fragments were detectable across all stages of the disease.

Conclusions: Elastin fragments generated by different proteases are elevated in lung cancer patients compared to healthy controls but differ in their presence. This demonstrates non-invasive biomarker potential of elastin fragments in serum from lung cancer patients and suggests that different pathological mechanisms may be responsible for the elastin turnover, warranting further validation in clinical trials.

Keywords: Biomarker; Cathepsin g; ECM; Elastin; Lung cancer; MMP; NSCLC; Neutrophil elastase; Proteinase 3; Serum.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Acta Neuropathol. 1999 Apr;97(4):399-407 - PubMed
    1. Am J Pathol. 2001 Feb;158(2):581-92 - PubMed
    1. Cancer Genet Cytogenet. 2004 Mar;149(2):98-106 - PubMed
    1. Clin Cancer Res. 2005 Feb 1;11(3):1086-92 - PubMed
    1. Adv Protein Chem. 2005;70:437-61 - PubMed

LinkOut - more resources